Company: ZVRA
Filing Date: 2025-04-16
Form Type: PRRN14A
Source: 0000897069-25-000815
Chunk: 11

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-16
Form: PRRN14A
Chunk 11
---
. The other issue of concern to me is the Company’s executive compensation, which I believe is excessive. In fact, stockholders seem to support this belief as they voted against the Company’s request to expand the available stock option pool after the Board had exhausted the existing pool. Unfortunately, to continue to provide themselves additional equity, management and the Board were able to circumvent the stockholder vote against the proposal by, among other things, greatly increasing the number of shares outstanding through a highly dilutive stock offering. I believe these poor governance practices have resulted in the stock languishing despite the approval and successful initial launch of MIPLYFFA™ and subsequent sale of the PRV. My goal as a long-term stockholder of Zevra is for an independent Board to act in the best interests of all stockholders and follow best practices in corporate governance and executive compensation. While my Nominees favor good corporate governance practices, they have not agreed to vote or act on the above corporate governance practices in any particular manner, as they take their fiduciary duties seriously and will only take action after being fully informed and determining what is in the best interests of the Company and its stockholders. Fortunately, this year you have the power to effect change at Zevra by voting for directors of the Company other than the members of the current Board of Directors. Specifically, we offer you a choice—an ability to vote for two exceptionally qualified director nominees who have the skills and commitment to help maximize stockholder value and realize Zevra’s true potential. This campaign is the result of careful consideration of the factors hampering Zevra’s potential under its current Board of Directors and lack of governance and the belief that adding the Nominees to the Board of Directors would bring sorely needed governance and be an effective contribution towards enhancing key strategic, operating and financial capabilities that would in turn improve stakeholder value. The Nominees recognize fully that as members of the Board they will owe fiduciary duties to all Zevra’s stockholders and are committed to maximizing value for all Zevra stockholders. The Proponent reserves the right to nominate additional nominees for any reason, including if the Company, by the appropriate corporate action, has increased or increases the number of directors to be elected at the Annual Meeting or the composition of the Board has changed prior to the Annual Meeting. Shares represented by proxies given to the Proponent may be voted for any substitute or additional nominees. To the extent it is not prohibited under the Bylaws and applicable law, the Proponent